Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Yann Schrodi
California State University Northridge, Department: Chemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Materia, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The investigator disclosed his equity interest in the company to Research & Sponsored Programs as a significant financial interest that reasonably appears to be related to his institutional responsibilities. The subject of the PHS-funded research is new olefin metathesis catalysts and processes. Because the company specializes in the commercialization of such processes, it is possible that advances in the field through the investigator’s research could affect the value of his equity interest in the company. Therefore, in accordance with the California State University, Northridge Policy on Financial Conflict of Interest Pertaining to PHS-Sponsored Projects, the Associate Vice President of Research and Graduate Studies determined that the investigator’s significant financial interest is related to PHS-funded research and could have a direct and significant effect on the design, conduct, or reporting of the research, constituting a financial conflict of interest. A management plan was created and has been appropriately followed.
New Robust Olefin Metathesis Catalysts Based on Non-Toxic and Abundant Low-Valent Molybdenum
Olefin metathesis is a synthetic method for the construction of carbon- carbon bonds, which has been instrumental in the discovery of novel medicinal agents. The proposed work aims to develop less toxic, 'greener', and cheaper olefin metathesis catalysts. These improvements will accelerate and facilitate the drug development process, and therefore ultimately enhance the public health.
Filed on May 16, 2019.
Tell us what you know about Yann Schrodi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Yann Schrodi filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Yann Schrodi | California State University Northridge | Conflict of Interest | Materia, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.